Sagent Pharmaceuticals (NASDAQ: SGNT) and Pfizer (NYSE:PFE) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.
This is a summary of current recommendations for Sagent Pharmaceuticals and Pfizer, as provided by MarketBeat.com.
||Strong Buy Ratings
Pfizer has a consensus target price of $38.80, suggesting a potential upside of 5.04%.
This table compares Sagent Pharmaceuticals and Pfizer’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Earnings & Valuation
This table compares Sagent Pharmaceuticals and Pfizer’s top-line revenue, earnings per share and valuation.
||Earnings Per Share
Pfizer has higher revenue and earnings than Sagent Pharmaceuticals. Sagent Pharmaceuticals is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.
Pfizer pays an annual dividend of $1.28 per share and has a dividend yield of 3.5%. Sagent Pharmaceuticals does not pay a dividend. Pfizer pays out 78.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 8 consecutive years.
Institutional and Insider Ownership
69.8% of Pfizer shares are held by institutional investors. 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Pfizer beats Sagent Pharmaceuticals on 11 of the 12 factors compared between the two stocks.
About Sagent Pharmaceuticals
Sagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company’s operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
Receive News & Ratings for Sagent Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagent Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.